Powder: -20°C for 3 years
In solvent: -80°C for 2 years
Octreotide acetate is a potent, long-acting synthetic somatostatin octapeptide analog that inhibits secretion of growth hormone.
Description | Octreotide acetate is a potent, long-acting synthetic somatostatin octapeptide analog that inhibits secretion of growth hormone. |
In vivo | Octreotide-treated groups show a significant reduction in the tumor volume compared to the saline group. Octreotide-PPSG (1.4 mg/kg, i.p.) shows greater antitumor effect than Octreotide-soln (100 μg/kg, i.p.). Octreotide-treatments results in significant inhibitory effect on the expression levels of SSTR2 and SSTR5 in primary HCC-bearing rats compared with the saline group. Octreotide-PPSG appears to inhibit the expression of SSTR2 and SSTR5 to a greater extent than that of Octreotide-soln treated group. A test dose of octreotide acetate significantly decreases the serum gastrin level to approximately one third of the baseline in 2 hr and the effect lasted approximately for 6 hr. On day 21, treatment with sustained-release formulation of octreotide acetatea (5 mg intramuscular, q 4 wk) is initiated. |
Animal Research | Octreotide (acetate) is formulated in saline.MiceThirty mice with HCC xenografts are randomLy divided into three groups: (A) Octreotide-soln group, (B) Octreotide-PPSG group, and (C) control group. Octreotide-soln group receives i.p. injection of 100 μg/kg octreotide-soln once a day and totally for consecutive 14 days. Octreotide-PPSG group receives a single subcutaneous injection of 1.4 mg/kg Octreotide-PPSG, and the injection volume is about 0.2 mL. Control group receives i.p. injection of saline once a day for consecutive 14 days. Treatment starts on the next day after injection of H22 hepatoma cell suspension and maintains for 14 days. Tumor growth is monitored by periodic caliper measurements on day 7 and day 14 post seeding. Tumor volumes (V) are calculated based on the length and width of tumor by Eq. RatTwelve male SD rats are divided into two groups, and housed in standard cages at 25°C, with free access to food and water for a week prior to the experiment. Rats are subcutaneously injected with Octreotidereotide solution (Octreotide-soln) or Octreotide-PPSG at an equivalent single dose of 20 mg/kg. The dose is determined based on the clinical dose of Octreotide-soln in human. Rats are fasted for 12 h before dosing and food is returned approximately 2 h post dosing. Blood samples are collected at predetermined time points using heparinized Eppendorf tubes. Immediately after collection, the blood samples are placed on ice until centrifuged at 3000 g for 10 min within 1 h. The plasma is collected and stored at ?20°C until analysis. |
Synonyms | Longastatin, Sandostatin, SMS 201995, SMS 201-995 (acetate), 醋酸奥曲肽 |
Molecular Weight | 1079.3 |
Formula | C51H70N10O12S2 |
CAS No. | 79517-01-4 |
Powder: -20°C for 3 years
In solvent: -80°C for 2 years
DMSO: 29 mg/mL
( < 1 mg/ml refers to the product slightly soluble or insoluble )
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Octreotide Acetate 79517-01-4 G蛋白偶联受体 Somatostatin SMS 201-995 inhibit SMS 201-995 (acetate) Octreotide Inhibitor SSTR Sandostatin Somatostatin Receptor Longastatin SSTRs SMS 201995 inhibitor